Mavens Is Acquired by Komodo Health

January 11, 2021

Mavens, a leader in cloud-based technology solutions, has been acquired by Komodo Health.

Mavens brings together Komodo’s Healthcare Map™ and software suite with enterprise applications from Mavens, creating the most advanced data-driven, enterprise platform for healthcare and life sciences.

This deal will enable customers to more efficiently and seamlessly put life-saving therapies into the hands of patients who need them most. Deal terms were not disclosed.

“This acquisition disrupts the status quo, unlocking a fundamentally different opportunity for life sciences companies to gain access to differentiated insights through technology,” said Arif Nathoo, MD, CEO and co-founder of Komodo Health. “Purchasing fragmented and costly data assets, custom solutions and expensive consulting projects will be a thing of the past as Komodo Health delivers a seamless, data-driven platform across R&D, Commercial, Medical Affairs and Patient workflows.”

“Customers will benefit from our cloud-based enterprise platform that offers access to a suite of software solutions powered by our industry-leading Healthcare Map,” added Web Sun, President and co-founder of Komodo Health. “This will revolutionize the value that healthcare and life sciences companies can now realize.”

“We are excited to join forces with Komodo Health to create a next-generation solution for the industry,” said Prasad Kanumury (PK), founder and CEO of Mavens. “Together, we will transform the way life sciences companies support patients and providers, ultimately reducing the burden of disease across the globe. This raises the bar and changes the expectations of the entire healthcare ecosystem.”

Together, Komodo and Mavens will expand their software capabilities, powered by insights from Komodo’s Healthcare Map™ — which tracks more than 320 million de-identified patient journeys. As the industry shifts toward a patient-centered data model, enterprise healthcare companies can end their reliance on legacy data aggregators. The acquisition will also accelerate Komodo’s global expansion, as Mavens currently operates in the U.S., U.K. and India.

The acquisition of Mavens also comes on the heels of continued financial investment in Komodo Health, which raised $44 million in Series D funding led by ICONIQ Growth. Previous investors Andreessen Horowitz, Oak HC/FT, IA Ventures, Felicis Ventures, and McKesson Ventures all participated in the round. This funding will accelerate Komodo Health’s ability to expand its Healthcare Map, platform, and solutions and further accelerate its mission to reduce the global burden of disease.

“We have long admired Komodo’s achievements and we believe the company’s unique approach has finally linked robust patient journey data with crucial workflows to achieve greater efficiency and better outcomes in healthcare,” said Caroline Xie, General Partner, ICONIQ Growth. “With the acquisition of Mavens, Komodo extends its strategy deeper into the life sciences enterprise and remains well capitalized to accelerate its impact across the entire healthcare ecosystem.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version